BIO-ID: O Futuro é Hoje!
[Página Institucional]
NOSSA EMPRESA
Em julho de 1982, dois bioengenheiros registraram a Bio-Id Ltda com o sonho de gerar tecnologia para o melhoramento da condição de vida das pessoas.
Em julho de 1990, a Bio-Id se destacou e alterou sua razão social para Bio-Id S.A., uma empresa transnacional de ponta em bioengenharia e nanotecnologia. Durante todo este tempo ratificou seu propósito sempre vinculado ao desenvolvimento de biotecnologia com responsabilidade social. Sua gestão dinâmica e corajosa implantou uma gestão de qualidade comprometida com o bem estar social.
Ética com os Direitos Humanos, Ética na Pesquisa com animais e, sobretudo, qualidade dos seus serviços e produtos marcam a política da qualidade da Bio-Id.
BIO-ID SEMPRE COM UMA SOLUÇÃO PARA VOCÊ.
SUA VIDA É NOSSA PRINCIPAL PREOCUPAÇÃO.
Conheça nossos serviços:
- Melhoramentos humanos
Marshall McLuhan escreveu que as mídias eram como extensões do homem. A Bio-Id tornou isso mais do que nunca uma realidade.
- Próteses biônicas de comunicação perfeitamente adaptadas ao corpo humano e integradas ao sistema nervoso central;
- Sistemas biônicos de ampliação dos sentidos;
- Conexão neural de dispositivos tecnológicos;
- Sistemas de controle biométrico através de implantes corporais;
- Computadores que funcionam com o mesmo princípio dos neurônios (chamados de neurocomputadores) permitem a perfeita integração homem/máquina.
A Bio-Id domina, hoje, biotecnologia com projetos sob demanda para a reestruturação cognitiva mediada por dispositivos computacionais. Melhorar suas capacidades cognitivas e recobrar funções perdidas é um compromisso.
Fonte da Imagem: MIT Media Relations
A Lei de Moore diz que o poder de processamento dos computadores atuais dobra a cada 18 meses, aliado às novas tecnologias, nossos equipamentos conseguem ser 7x mais rápidos nos próximos anos. A interação entre dispositivos e pessoas é natural. Disponibilizamos horizontes expandidos para a compensação de sentidos graças às nossas pesquisas de ponta.
Nossos projetos mais inovadores mesclam a bioengenharia com a nanotecnologia, produzindo sistemas únicos de conectividade relacionada com a computação em nuvem em uma pessoa nativa tecnologicamente. Você poderá em breve compartilhar memórias e registros facilmente. As tecnologias necessárias para a produção deste tipo de realidade já estão em desenvolvimento pela Bio-Id.
Subsidiary of Johnson & Johnson, Centocor is a biotechnology company that was founded in Philadelphia in 1979 with an initial goal of developing new diagnostic assays using monoclonal antibody technology. In 1982 Centocor developed their first product approved by the U.S. Food and Drug Administration (FDA) — a diagnostic test used to detect the rabies virus, and in that same year transitioned into a publicly traded company. Subsequently, the company moved to a larger facility in Malvern, Pennsylvania (a northwest suburb of Philadelphia). In 1984, Centocor opened an overseas plant in Leiden, the Netherlands. Eighteen years after its foundation, (in 1997), Centocor achieved its first year of operating profitability. In 1998, Centocor divested itself of its diagnostic division and launched its top-selling monoclonal antibody Remicade (infliximab) for its first FDA approved indication in Crohn’s Disease. In 1999, Centocor became a wholly owned subsidiary of Johnson & Johnson, the worldwide manufacturer and marketer of healthcare products. Subsequently, Remicade’s market has expanded with approvals for rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, ulcerative colitis, and pediatric Crohn’s disease. Remicade was approved for plaque psoriasis in September 2006. Centocor also markets ReoPro (abciximab), a biologic agent indicated as an adjunct to coronary angioplasty (PTCA). Since being acquired by Johnson and Johnson, Centocor has increased its annual sales from approximately $500 million to more than $2 billion. During the same period, research and development investment increased from $75 million to more than $300 million. In 2004 Centocor purchased a new manufacturing plant in St. Louis, Missouri, and is currently opening a new manufacturing facility in County Cork, Ireland. The Dutch plant has been expanded substantially with a $250 million investment in additional production facilities, which were opened in 2006.
Especializações
Biotechnology from R&D to manufacturing and marketing
-
Site
-
Setor
Biotecnologia
-
Tipo
Empresa de capital aberto
-
Sede
Estados Unidos
-
Tamanho da empresa
1.001-5.000 funcionários
-
Fundada em
1979
is a biotechnology company that was founded in Philadelphia in 1979 with an initial goal of developing new diagnostic assays using monoclonal antibody technology.
Contents
[hide]
History[edit]
In 1982 Centocor transitioned into a publicly traded company. Subsequently, the company moved to a larger facility in Malvern, Pennsylvania (a northwest suburb of Philadelphia). In 1984, Centocor opened an overseas plant in Leiden, the Netherlands.
In 1997, eighteen years after its foundation, Centocor achieved its first year of operating profitability.[citation needed] In 1998, Centocor sold its diagnostic division to Fujirebio, Inc..[1]
In 1999, Centocor became a wholly owned subsidiary of Johnson & Johnson, the worldwide manufacturer and marketer of healthcare products. Since being acquired by Johnson and Johnson, Centocor has increased its annual sales from approximately $500 million to more than $2 billion. During the same period, research and development investment increased from $75 million to more than $300 million.[citation needed]
In 2004 Centocor purchased a new manufacturing plant in St. Louis, Missouri, and is currently opening a new manufacturing facility in County Cork, Ireland. The Dutch plant has been expanded substantially with a $250 million investment in additional production facilities, which were opened in 2006.[citation needed]
In 2007, Centocor broke new ground in advertising by releasing Innerstate, believed to be the first theatrically released documentary film both created and entirely funded by a drug company, to promote Remicade (Infliximab).[2]
In 2008, Centocor, Inc. and Ortho Biotech Inc. merged to form Centocor Ortho Biotech Inc.
In June 2010 Centocor Ortho Biotech acquired RespiVert, a privately held drug discovery company focused on developing small-molecule, inhaled therapies for the treatment of pulmonary diseases.[3]
In June 2011 Centocor Ortho Biotech changed its name to Janssen Biotech, Inc. as part of a global effort to unite the Janssen Pharmaceutical Companies around the world under a common identity.
In December 2014, the company announced it would co-develop MacroGenics cancer drug candidate (MGD011) which targets both CD19 and CD3 proteins in treating B-cellmalignant tumours. This could net MacroGenics up to $700 million.[4]
In January 2015, the company announced it will utilise Isis Pharmaceuticals‘ Rna-targeting technology to discover and develop antisense drugs targeting autoimmune disorders of the gastrointestinal tract, with the partnership potentially generating up to $835 million for Isis.[5]
Products[edit]
In 1984 Centocor developed their first product approved by the U.S. Food and Drug Administration (FDA) — a diagnostic test used to detect the rabies virus.[citation needed]
In 1998 the company launched its top-selling monoclonal antibody Remicade (infliximab) for its first FDA approved indication in Crohn’s Disease. Subsequently, Remicade’s market has expanded with approvals for rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, ulcerative colitis, and pediatric Crohn’s disease. Remicade was approved for plaque psoriasis in September 2006.
Centocor also markets ReoPro (abciximab), a biologic agent indicated as an adjunct to coronary angioplasty (PTCA).
In 2009, the U.S. FDA approved Simponi, a human monoclonal antibody for treatment for arthritis, which was co-developed with Medarex, Inc.
https://www.janssenbiotech.com/company/history
https://www.sciencecenter.org/companies/success-stories/centocor-ortho-biotech-inc
http://www.pharmaceutical-technology.com/projects/centocor/